Rankings
▼
Calendar
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q1 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$68M
Net Income
-$66M
EPS (Diluted)
$-1.27
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$63M
Free Cash Flow
-$65M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$346M
Total Liabilities
$40M
Stockholders' Equity
$307M
Cash & Equivalents
$327M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$68M
-$16M
-314.0%
Net Income
-$66M
-$16M
-311.8%
← FY 2019
All Quarters
Q2 2019 →
KNSA Q1 2019 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena